Unknown

Dataset Information

0

Protein kinase C? is a therapeutic target in malignant melanoma with NRAS mutation.


ABSTRACT: NRAS is the second most frequently mutated gene in melanoma. Previous reports have demonstrated the sensitivity of cancer cell lines carrying KRAS mutations to apoptosis initiated by inhibition of protein kinase C? (PKC?). Here, we report that PKC? inhibition is cytotoxic in melanomas with primary NRAS mutations. Novel small-molecule inhibitors of PKC? were designed as chimeric hybrids of two naturally occurring PKC? inhibitors, staurosporine and rottlerin. The specific hypothesis interrogated and validated is that combining two domains of two naturally occurring PKC? inhibitors into a chimeric or hybrid structure retains biochemical and biological activity and improves PKC? isozyme selectivity. We have devised a potentially general synthetic protocol to make these chimeric species using Molander trifluorborate coupling chemistry. Inhibition of PKC?, by siRNA or small molecule inhibitors, suppressed the growth of multiple melanoma cell lines carrying NRAS mutations, mediated via caspase-dependent apoptosis. Following PKC? inhibition, the stress-responsive JNK pathway was activated, leading to the activation of H2AX. Consistent with recent reports on the apoptotic role of phospho-H2AX, knockdown of H2AX prior to PKC? inhibition mitigated the induction of caspase-dependent apoptosis. Furthermore, PKC? inhibition effectively induced cytotoxicity in BRAF mutant melanoma cell lines that had evolved resistance to a BRAF inhibitor, suggesting the potential clinical application of targeting PKC? in patients who have relapsed following treatment with BRAF inhibitors. Taken together, the present work demonstrates that inhibition of PKC? by novel small molecule inhibitors causes caspase-dependent apoptosis mediated via the JNK-H2AX pathway in melanomas with NRAS mutations or BRAF inhibitor resistance.

SUBMITTER: Takashima A 

PROVIDER: S-EPMC4160068 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.

Takashima Asami A   English Brandon B   Chen Zhihong Z   Cao Juxiang J   Cui Rutao R   Williams Robert M RM   Faller Douglas V DV  

ACS chemical biology 20140218 4


NRAS is the second most frequently mutated gene in melanoma. Previous reports have demonstrated the sensitivity of cancer cell lines carrying KRAS mutations to apoptosis initiated by inhibition of protein kinase Cδ (PKCδ). Here, we report that PKCδ inhibition is cytotoxic in melanomas with primary NRAS mutations. Novel small-molecule inhibitors of PKCδ were designed as chimeric hybrids of two naturally occurring PKCδ inhibitors, staurosporine and rottlerin. The specific hypothesis interrogated a  ...[more]

Similar Datasets

| S-EPMC7380552 | biostudies-literature
| S-EPMC6737096 | biostudies-literature
| S-EPMC3335938 | biostudies-literature
| S-EPMC4431617 | biostudies-literature
| S-EPMC3639697 | biostudies-literature
| S-EPMC10027906 | biostudies-literature
| S-EPMC4418029 | biostudies-literature
| S-EPMC3760692 | biostudies-literature
| S-EPMC3600159 | biostudies-literature
| S-EPMC4258185 | biostudies-literature